EE9900095A - Tagasivoolu inhibiitorid - Google Patents

Tagasivoolu inhibiitorid

Info

Publication number: EE9900095A
Authority: EE; Estonia
Prior art keywords: reflux inhibitors; reflux; inhibitors
Prior art date: 1996-09-18

Application number

EEP199900095A

Other languages

English (en)

Other versions

EE03952B1 (et

Inventor

L. R. Andrews Paul

Lehmann Anders

Original Assignee

Astra Aktiebolag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-18

Filing date

1997-09-15

Publication date

1999-10-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20403936&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE9900095(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-09-15 Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag

1999-10-15 Publication of EE9900095A publication Critical patent/EE9900095A/et

2003-02-17 Publication of EE03952B1 publication Critical patent/EE03952B1/et

Links

239000003112 inhibitor Substances 0.000 title 1
238000010992 reflux Methods 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/9426—GABA, i.e. gamma-amino-butyrate
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Pathology (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
General Physics & Mathematics (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Otolaryngology (AREA)
Hospice & Palliative Care (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

EEP199900095A 1996-09-18 1997-09-15 Tagasivoolu inhibiitorid EE03952B1 (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9603408A SE9603408D0 (sv)	1996-09-18	1996-09-18	Medical use
PCT/SE1997/001555 WO1998011885A1 (en)	1996-09-18	1997-09-15	Reflux inhibitors

Publications (2)

Publication Number	Publication Date
EE9900095A true EE9900095A (et)	1999-10-15
EE03952B1 EE03952B1 (et)	2003-02-17

Family

ID=20403936

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP199900095A EE03952B1 (et)	1996-09-18	1997-09-15	Tagasivoolu inhibiitorid

Country Status (35)

Country	Link
US (2)	US6117908A (et)
EP (2)	EP1344524B1 (et)
JP (1)	JP4098832B2 (et)
KR (2)	KR100568659B1 (et)
CN (1)	CN1117560C (et)
AR (1)	AR007747A1 (et)
AT (2)	ATE249212T1 (et)
AU (1)	AU714370B2 (et)
BR (1)	BR9711400A (et)
CA (1)	CA2265615C (et)
CZ (1)	CZ299997B6 (et)
DE (2)	DE69736445T2 (et)
DK (2)	DK0936906T3 (et)
EE (1)	EE03952B1 (et)
ES (2)	ES2268227T3 (et)
HK (2)	HK1022100A1 (et)
HU (1)	HU224968B1 (et)
ID (1)	ID19621A (et)
IL (1)	IL128961A (et)
IS (2)	IS2329B (et)
MY (1)	MY122020A (et)
NO (1)	NO326837B1 (et)
NZ (2)	NZ334495A (et)
PL (1)	PL190028B1 (et)
PT (2)	PT936906E (et)
RU (1)	RU2199316C2 (et)
SA (1)	SA97180522B1 (et)
SE (1)	SE9603408D0 (et)
SI (2)	SI1344524T1 (et)
SK (1)	SK285744B6 (et)
TR (1)	TR199900591T2 (et)
TW (1)	TW548104B (et)
UA (1)	UA61081C2 (et)
WO (1)	WO1998011885A1 (et)
ZA (1)	ZA977969B (et)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0934061T6 (en)	1996-07-24	2015-01-26	Warner Lambert Co	Isobutylgaba and its derivatives for the treatment of pain
US6127418A (en) *	1997-08-20	2000-10-03	Warner-Lambert Company	GABA analogs to prevent and treat gastrointestinal damage
WO1999008670A1 (en) *	1997-08-20	1999-02-25	Guglietta, Antonio	Gaba analogs to prevent and treat gastrointestinal damage
EP0974351A3 (en) *	1998-04-24	2000-12-13	Jouveinal	Medicament for preventing and treating gastrointestinal damage
US20080207755A1 (en) *	2000-05-31	2008-08-28	Pfizer Inc	Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
US7164034B2 (en)	1999-06-10	2007-01-16	Pfizer Inc.	Alpha2delta ligands for fibromyalgia and other disorders
US7319095B2 (en) *	1999-12-09	2008-01-15	Astrazeneca Ab	Use of GABAB receptor agonists
SE9904507D0 (sv)	1999-12-09	1999-12-09	Astra Ab	New compounds
SE9904508D0 (sv) *	1999-12-09	1999-12-09	Astra Ab	New compounds
TWI256314B (en) *	2000-02-09	2006-06-11	Mitsubishi Pharma Corp	Preventive-therapeutical medicament for gastroesophageal reflux disease
WO2002096404A1 (en) *	2001-05-29	2002-12-05	Depomed Development Ltd	Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
SE0102055D0 (sv) *	2001-06-08	2001-06-08	Astrazeneca Ab	New Compounds
SE0102058D0 (sv) *	2001-06-08	2001-06-08	Astrazeneca Ab	New Salts II
AR033779A1 (es) *	2001-06-08	2004-01-07	Astrazeneca Ab	Compuestos utiles en la enfermedad de reflujo
SE0102057D0 (sv) *	2001-06-08	2001-06-08	Astrazeneca Ab	New Salts I
GB0209481D0 (en) *	2002-04-24	2002-06-05	Novartis Ag	Organic compounds
SE0201939D0 (sv) *	2002-06-20	2002-06-20	Astrazeneca Ab	New combination
SE0201940D0 (sv) *	2002-06-20	2002-06-20	Astrazeneca Ab	New combination II
SE0201943D0 (sv) *	2002-06-20	2002-06-20	Astrazeneca Ab	New use
US7964609B2 (en)	2002-06-20	2011-06-21	Astrazeneca Ab	Use of mGluR5 antagonists for the treatment of gerd
GB0226434D0 (en) *	2002-11-13	2002-12-18	Astrazeneca Ab	Combination product
JP2006513257A (ja) *	2002-12-13	2006-04-20	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	線維筋痛症および他の障害を処置するためのプレガバリン誘導体
KR101140559B1 (ko) *	2003-08-20	2012-07-05	제노포트 인코포레이티드	아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법
EP2354120A1 (en)	2003-08-20	2011-08-10	XenoPort, Inc.	Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
KR20060120612A (ko) *	2003-09-12	2006-11-27	얀센 파마슈티카 엔.브이.	키메라 ｇａｂａｂ 수용체
US20050220873A1 (en) *	2004-04-02	2005-10-06	Chien-Hsuan Han	Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
US20050220863A1 (en) *	2004-04-02	2005-10-06	Chien-Hsuan Han	Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
US8007827B2 (en) *	2004-04-02	2011-08-30	Impax Laboratories, Inc.	Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20050226927A1 (en) *	2004-04-02	2005-10-13	Impax Laboratories, Inc.	Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
SE0401653D0 (sv)	2004-06-24	2004-06-24	Astrazeneca Ab	New compounds
WO2006050472A2 (en) *	2004-11-03	2006-05-11	Xenoport, Inc.	Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
US7566738B2 (en) *	2004-11-03	2009-07-28	Xenoport, Inc.	Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
WO2006071186A1 (en) *	2004-12-27	2006-07-06	Astrazeneca Ab	Use of gabab receptor agonists
JP2009521426A (ja) *	2005-12-23	2009-06-04	アストラゼネカ・アクチエボラーグ	ヘテロ環ｇａｂａ−ｂモジュレーター
BRPI0620373A2 (pt) *	2005-12-23	2011-11-08	Astrazeneca Ab	composto e sais farmaceuticamente e farmacologicamente aceitáveis dos mesmos, e enantiÈmeros do composto e sais dos mesmos, uso dos mesmos, opcionalmente em combinação com um agonista do receptor de gabab,e , composição farmaceutica
KR20080091452A (ko) *	2005-12-23	2008-10-13	아스트라제네카 아베	위장 장애의 치료를 위한 이미다졸 유도체
KR20080090449A (ko) *	2005-12-23	2008-10-08	아스트라제네카 아베	Ｇｅｒｄ 및 ｉｂｓ의 치료를 위한 피라졸
AU2006327317B2 (en)	2005-12-23	2010-11-25	Astrazeneca Ab	GABA-B receptor modulators
WO2008033572A1 (en) *	2006-09-15	2008-03-20	Xenoport, Inc.	Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
ZA200904573B (en)	2006-12-22	2010-09-29	Ironwood Pharmaceuticals Inc	Compositions comprising bile acid sequestrants for treating esophageal disorders
JP2010515754A (ja) *	2007-01-11	2010-05-13	ゼノポート，インコーポレイティド	Ｒ−バクロフェンのプロドラッグの徐放性経口剤形及び治療方法
CN101679444A (zh) *	2007-04-18	2010-03-24	阿斯利康(瑞典)有限公司	具有正变构gabab受体调节剂作用的黄嘌呤化合物
TW200908957A (en) *	2007-06-15	2009-03-01	Xenoport Inc	Use of prodrugs of GABA analogs, antispasticity agents, and prodrugs of GABAB receptor agonists for treating spasticity
WO2009014491A1 (en) *	2007-07-25	2009-01-29	Astrazeneca Ab	The use of (3-amino-2-fluoropropyl) phosphinic acid for treatment of nerd
WO2009061934A1 (en) *	2007-11-06	2009-05-14	Xenoport, Inc.	Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain
CA2710538A1 (en) *	2008-01-25	2009-07-30	Xenoport, Inc.	Crystalline form of a (3s)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
EP2250148B1 (en)	2008-01-25	2016-08-17	XenoPort, Inc.	Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
WO2009094577A2 (en)	2008-01-25	2009-07-30	Xenoport, Inc.	Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
US20100137442A2 (en) *	2008-02-01	2010-06-03	Xenoport, Inc.	Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
US8993639B2 (en) *	2008-03-20	2015-03-31	Burt Shulman	Compound and method for treatment of gastroesophageal reflux
US8299291B2 (en) *	2008-08-07	2012-10-30	Xenoport, Inc.	Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
US7989641B2 (en)	2008-08-07	2011-08-02	Xenoport, Inc.	Methods of synthesizing N-hydroxysuccinimidyl carbonates
CN102341099A (zh)	2009-03-03	2012-02-01	什诺波特有限公司	R-巴氯芬前药的持续释放口服剂型
JP2012524065A (ja) *	2009-04-17	2012-10-11	ゼノポート，インコーポレーテッド	ＧＡＢＡＢ受容体リガンドとしてのγ−アミノ酪酸誘導体
WO2011113904A1 (en)	2010-03-17	2011-09-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
WO2013023155A1 (en)	2011-08-11	2013-02-14	Xenoport, Inc.	Anhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use
EP2854774A4 (en)	2012-06-01	2015-11-18	Lynn Health Science Inst Inc	METHODS OF TREATING INSOMNIA
TW202412754A (zh) *	2022-06-07	2024-04-01	瑞士商意梭凱普公司	應用於食道黏膜的包含逆流抑制劑的藥物傳遞系統

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU594424B2 (en) *	1986-01-03	1990-03-08	University Of Melbourne, The	Gastro-oesophageal reflux composition
NO882881L (no) *	1988-06-29	1990-01-02	Trond Nilsen	Anordning for lengdekorrugering av metallplater.
WO1990009096A2 (en) *	1989-02-03	1990-08-23	Cambridge Neuroscience Research, Inc.	Method of screening and classifying compounds
GB9117716D0 (en) *	1991-08-16	1991-10-02	Lynxvale Ltd	Gaba derivatives and their therapeutic application
ES2174897T3 (es) *	1992-01-22	2002-11-16	Glaxo Group Ltd	Uso medico de agonistas de beta-adrenoceptores atipicos.
GB9408064D0 (en) *	1994-04-22	1994-06-15	Merck Sharp & Dohme	Nucleic acids
US5491134A (en) *	1994-09-16	1996-02-13	Bristol-Myers Squibb Company	Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5656730A (en) *	1995-04-07	1997-08-12	Enzon, Inc.	Stabilized monomeric protein compositions

1996
- 1996-09-18 SE SE9603408A patent/SE9603408D0/xx unknown
1997
- 1997-09-04 AR ARP970104051A patent/AR007747A1/es unknown
- 1997-09-04 ZA ZA9707969A patent/ZA977969B/xx unknown
- 1997-09-12 ID IDP973172A patent/ID19621A/id unknown
- 1997-09-12 TW TW086113275A patent/TW548104B/zh not_active IP Right Cessation
- 1997-09-15 US US08/952,400 patent/US6117908A/en not_active Expired - Lifetime
- 1997-09-15 PL PL97332497A patent/PL190028B1/pl not_active IP Right Cessation
- 1997-09-15 AU AU44064/97A patent/AU714370B2/en not_active Ceased
- 1997-09-15 EE EEP199900095A patent/EE03952B1/et not_active IP Right Cessation
- 1997-09-15 PT PT97942346T patent/PT936906E/pt unknown
- 1997-09-15 SI SI9730749T patent/SI1344524T1/sl unknown
- 1997-09-15 KR KR1020057018539A patent/KR100568659B1/ko not_active IP Right Cessation
- 1997-09-15 KR KR1019997002239A patent/KR100553294B1/ko not_active IP Right Cessation
- 1997-09-15 HU HU9903825A patent/HU224968B1/hu not_active IP Right Cessation
- 1997-09-15 NZ NZ334495A patent/NZ334495A/xx not_active IP Right Cessation
- 1997-09-15 BR BR9711400A patent/BR9711400A/pt not_active Application Discontinuation
- 1997-09-15 DK DK97942346T patent/DK0936906T3/da active
- 1997-09-15 PT PT03013667T patent/PT1344524E/pt unknown
- 1997-09-15 NZ NZ504244A patent/NZ504244A/xx not_active IP Right Cessation
- 1997-09-15 EP EP03013667A patent/EP1344524B1/en not_active Expired - Lifetime
- 1997-09-15 AT AT97942346T patent/ATE249212T1/de active
- 1997-09-15 WO PCT/SE1997/001555 patent/WO1998011885A1/en active Application Filing
- 1997-09-15 TR TR1999/00591T patent/TR199900591T2/xx unknown
- 1997-09-15 EP EP97942346A patent/EP0936906B1/en not_active Expired - Lifetime
- 1997-09-15 ES ES03013667T patent/ES2268227T3/es not_active Expired - Lifetime
- 1997-09-15 ES ES97942346T patent/ES2206749T3/es not_active Expired - Lifetime
- 1997-09-15 SI SI9730594T patent/SI0936906T1/xx unknown
- 1997-09-15 JP JP51458198A patent/JP4098832B2/ja not_active Expired - Fee Related
- 1997-09-15 CZ CZ0093099A patent/CZ299997B6/cs not_active IP Right Cessation
- 1997-09-15 DE DE69736445T patent/DE69736445T2/de not_active Expired - Lifetime
- 1997-09-15 RU RU99107969/14A patent/RU2199316C2/ru not_active IP Right Cessation
- 1997-09-15 UA UA99031298A patent/UA61081C2/uk unknown
- 1997-09-15 CN CN97199600A patent/CN1117560C/zh not_active Expired - Fee Related
- 1997-09-15 IL IL12896197A patent/IL128961A/en not_active IP Right Cessation
- 1997-09-15 AT AT03013667T patent/ATE334700T1/de active
- 1997-09-15 DK DK03013667T patent/DK1344524T3/da active
- 1997-09-15 SK SK305-99A patent/SK285744B6/sk not_active IP Right Cessation
- 1997-09-15 DE DE69724809T patent/DE69724809T2/de not_active Expired - Lifetime
- 1997-09-15 CA CA002265615A patent/CA2265615C/en not_active Expired - Fee Related
- 1997-09-16 MY MYPI97004296A patent/MY122020A/en unknown
- 1997-10-27 SA SA97180522A patent/SA97180522B1/ar unknown
1999
- 1999-03-15 IS IS5001A patent/IS2329B/is unknown
- 1999-03-17 NO NO19991287A patent/NO326837B1/no not_active IP Right Cessation
2000
- 2000-02-24 HK HK00101114A patent/HK1022100A1/xx not_active IP Right Cessation
- 2000-09-08 US US09/658,242 patent/US6664069B1/en not_active Expired - Fee Related
2003
- 2003-12-23 HK HK03109347A patent/HK1057004A1/xx not_active IP Right Cessation
2007
- 2007-03-19 IS IS8623A patent/IS2538B/is unknown

Also Published As

Publication number	Publication date
JP4098832B2 (ja)	2008-06-11
ATE249212T1 (de)	2003-09-15
TR199900591T2 (xx)	1999-07-21
KR100568659B1 (ko)	2006-04-07
DE69736445T2 (de)	2007-03-15
IL128961A0 (en)	2000-02-17
NZ334495A (en)	2000-09-29
NO326837B1 (no)	2009-02-23
BR9711400A (pt)	1999-08-17
KR100553294B1 (ko)	2006-02-22
ATE334700T1 (de)	2006-08-15
EP1344524B1 (en)	2006-08-02
NO991287L (no)	1999-03-17
AR007747A1 (es)	1999-11-10
IS5001A (is)	1999-03-15
PT936906E (pt)	2003-12-31
NO991287D0 (no)	1999-03-17
CN1237105A (zh)	1999-12-01
ES2268227T3 (es)	2007-03-16
DK1344524T3 (da)	2006-10-30
US6117908A (en)	2000-09-12
PT1344524E (pt)	2006-11-30
ES2206749T3 (es)	2004-05-16
NZ504244A (en)	2000-09-29
CA2265615C (en)	2007-01-30
ID19621A (id)	1998-07-23
DE69724809T2 (de)	2004-07-15
AU4406497A (en)	1998-04-14
WO1998011885A1 (en)	1998-03-26
DE69736445D1 (de)	2006-09-14
KR20050101237A (ko)	2005-10-20
MY122020A (en)	2006-03-31
EP0936906B1 (en)	2003-09-10
ZA977969B (en)	1998-03-18
HU224968B1 (en)	2006-04-28
HUP9903825A2 (hu)	2001-05-28
PL190028B1 (pl)	2005-10-31
SI0936906T1 (en)	2004-02-29
US6664069B1 (en)	2003-12-16
SE9603408D0 (sv)	1996-09-18
HUP9903825A3 (en)	2001-06-28
SK30599A3 (en)	2000-01-18
DK0936906T3 (da)	2003-11-24
SA97180522B1 (ar)	2006-04-04
CA2265615A1 (en)	1998-03-26
HK1057004A1 (en)	2004-03-12
SI1344524T1 (sl)	2006-12-31
AU714370B2 (en)	1999-12-23
CZ93099A3 (cs)	1999-09-15
PL332497A1 (en)	1999-09-13
TW548104B (en)	2003-08-21
RU2199316C2 (ru)	2003-02-27
UA61081C2 (uk)	2003-11-17
HK1022100A1 (en)	2000-07-28
EP1344524A1 (en)	2003-09-17
EP0936906A1 (en)	1999-08-25
KR20000036185A (ko)	2000-06-26
IS2538B (is)	2009-09-15
DE69724809D1 (de)	2003-10-16
IS8623A (is)	2007-03-19
CZ299997B6 (cs)	2009-01-14
IL128961A (en)	2004-08-31
CN1117560C (zh)	2003-08-13
JP2001501604A (ja)	2001-02-06
EE03952B1 (et)	2003-02-17
SK285744B6 (sk)	2007-07-06
IS2329B (is)	2008-01-15

Legal Events

Date	Code	Title	Description
2004-02-16	KB4A	Valid patent at the end of a year	Effective date: 20031231
2005-02-15	KB4A	Valid patent at the end of a year	Effective date: 20041231
2006-02-15	KB4A	Valid patent at the end of a year	Effective date: 20051231
2007-02-15	KB4A	Valid patent at the end of a year	Effective date: 20061231
2008-02-15	KB4A	Valid patent at the end of a year	Effective date: 20071231
2009-02-16	KB4A	Valid patent at the end of a year	Effective date: 20081231
2010-02-15	KB4A	Valid patent at the end of a year	Effective date: 20091231
2011-02-15	KB4A	Valid patent at the end of a year	Effective date: 20101231
2013-06-17	MM4A	Lapsed by not paying the annual fees	Effective date: 20120915

Publication	Publication Date	Title
DE69724809D1 (de)	2003-10-16	Refluxinhibitoren
FI963597A (fi)	1996-11-14	Isoprenyylitransferaasi-inhibiittoreita
NO972930D0 (no)	1997-06-23	Fibronectin-adhesjonsinhibitorer
FI972160A (fi)	1997-05-22	Matriisimetalloproteaasi-inhibiittorit
ID19198A (id)	1998-06-28	Inhibitor metaloprotease heterosiklik
DK1004669T3 (da)	2007-08-27	Hidtil ukendte differentieringsinhibitor
NO20002121D0 (no)	2000-04-26	Benzotiazol-protein-tyrosin-kinaseinhibitorer
DK1027332T3 (da)	2004-10-04	Hidtil ukendte lactametalloproteaseinhibitorer
ID18416A (id)	1998-04-09	Inhibitor metaloprotease diheterosiklik
DK0958287T3 (da)	2003-01-20	Sulfamidmetalloprotease-inhibitorer
ID18141A (id)	1998-03-05	Inhibitor metaloprotease 1,3-diheterosiklik
LV12150A (lv)	1998-10-20	Farneziltransferazes inhibitori
ID18995A (id)	1998-05-28	Amida-amida inhibitor apo b-sekresi/mtp
ATE268781T1 (de)	2004-06-15	Thrombininhibitoren
NO20003256L (no)	2000-06-22	ACE inhibitor-MMP inhibitor kombinasjoner
ID18417A (id)	1998-04-09	Inhibitor ditentat metaloprotease
FI971156A0 (fi)	1997-03-19	5alfa-reduktaasi-inhibiittoreita
DE69733263D1 (de)	2005-06-16	Markierte elastase-inhibitoren
ATE252547T1 (de)	2003-11-15	Matrixmetalloproteinaseinhibitoren
DE69731664D1 (de)	2004-12-23	Thrombininhibitoren
DE69720957T2 (de)	2004-01-29	Ace-hemmer
PT948483E (pt)	2002-08-30	Inibidores da farnesil-transferase
BR9610514A (pt)	1999-03-30	Inibidores cicloantihelmínticos
CY2007006I2 (el)	2009-11-04	Αναστολεις συνθεσεις απολιποπρωτεϊνης-β